SenzaGen AB Cash Flow Conversion Efficiency
SenzaGen AB cash flow conversion efficiency. Based on the latest financial reports, SenzaGen AB (SENZA) has a cash flow conversion efficiency ratio of -0.052x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (Skr-3.85 Million ≈ $-414.75K USD) by net assets (Skr74.24 Million ≈ $7.99 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Cash Flow Conversion Efficiency of SenzaGen AB (2014–2024)
Cash flow conversion efficiency of SenzaGen AB from 2014 to 2024. This chart illustrates how SenzaGen AB's cash flow conversion efficiency has evolved over time, based on yearly financial data. View SenzaGen AB share price for real-time trading data and today's change.
SenzaGen AB Cash Flow Conversion Ratio Explained
SenzaGen AB cash flow conversion ratio divides operating cash flow by net assets, so a higher ratio means more cash generated from each unit of shareholder equity.
SenzaGen AB Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of SenzaGen AB ranked by their cash flow conversion efficiency. Also see SenzaGen AB (SENZA) market capitalisation for the company's overall valuation and market capitalisation.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Posco C&C Stl
KO:058430
|
0.033x |
|
111 Inc
NASDAQ:YI
|
-3.363x |
|
Interwood-Xylemporia A.T.E.N.E.
AT:XYLEK
|
0.043x |
|
Critical Resources Ltd
AU:CRR
|
-0.030x |
|
Immo Mcc NV
BR:MCC
|
N/A |
|
VIRINCHI ORD (BSE)
NSE:VIRINCHI
|
0.014x |
|
NextTrip Inc
NASDAQ:NTRP
|
-0.316x |
|
Hoth Therapeutics Inc
NASDAQ:HOTH
|
-0.362x |
Annual Cash Flow Conversion Efficiency for SenzaGen AB (2014–2024)
The table below shows the annual cash flow conversion efficiency of SenzaGen AB from 2014 to 2024. Review how much free cash does SenzaGen AB generate to assess how much free cash flow the company generates relative to operating cash flow.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | Skr86.64 Million ≈ $9.32 Million |
Skr-9.33 Million ≈ $-1.00 Million |
-0.108x | +55.75% |
| 2023-12-31 | Skr67.61 Million ≈ $7.28 Million |
Skr-16.45 Million ≈ $-1.77 Million |
-0.243x | -35.83% |
| 2022-12-31 | Skr89.70 Million ≈ $9.65 Million |
Skr-16.07 Million ≈ $-1.73 Million |
-0.179x | +5.86% |
| 2021-12-31 | Skr110.24 Million ≈ $11.86 Million |
Skr-20.98 Million ≈ $-2.26 Million |
-0.190x | +30.17% |
| 2020-12-31 | Skr107.79 Million ≈ $11.60 Million |
Skr-29.38 Million ≈ $-3.16 Million |
-0.273x | -17.68% |
| 2019-12-31 | Skr134.21 Million ≈ $14.44 Million |
Skr-31.08 Million ≈ $-3.34 Million |
-0.232x | +14.26% |
| 2018-12-31 | Skr85.94 Million ≈ $9.25 Million |
Skr-23.21 Million ≈ $-2.50 Million |
-0.270x | -134.27% |
| 2017-12-31 | Skr101.01 Million ≈ $10.87 Million |
Skr-11.65 Million ≈ $-1.25 Million |
-0.115x | +61.09% |
| 2016-12-31 | Skr32.71 Million ≈ $3.52 Million |
Skr-9.69 Million ≈ $-1.04 Million |
-0.296x | -96.27% |
| 2015-12-31 | Skr41.61 Million ≈ $4.48 Million |
Skr-6.28 Million ≈ $-675.94K |
-0.151x | -129.67% |
| 2014-12-31 | Skr2.05 Million ≈ $220.61K |
Skr1.04 Million ≈ $112.24K |
0.509x | -- |
About SenzaGen AB
SenzaGen AB provides non-animal tests for assessing allergenicity. The company offers GARD skin OECD 442E, GARD skin dose-response, GARD skin medical device; and GARD air, a respiratory sensitization assessment. It also provides biological evaluation, in vitro biocompatibility testing, cytotoxicity, irritation, and skin sensitization medical device services; advisory services for medical devices;… Read more